Drug‐Induced Liver Injury: A Mexican View
Raúl Contreras Omaña, Rosalba Moreno Alcántar, Eira Cerda Reyes – 9 March 2022
Viral Kinetics of an Acute Hepatitis B Virus Subgenotype F1b Infection in a Mexican Subject
Arturo Panduro, Sonia Roman, Nora A. Fierro, João R. Rebello‐Pinho – 9 March 2022
Making child’s play of tolerance: Defining the immune‐viral interplay during combination entecavir and pegylated interferon therapy for immune‐tolerant hepatitis B infection
Jessica Howell, Margaret Hellard – 8 March 2022
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer
Mina Komuta, Akihisa Ueno, Michiie Sakamoto – 8 March 2022
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Francesca Romana Ponziani, Angela De Luca, Anna Picca, Emanuele Marzetti, Valentina Petito, Federica Del Chierico, Sofia Reddel, Francesco Paroni Sterbini, Maurizio Sanguinetti, Lorenza Putignani, Antonio Gasbarrini, Maurizio Pompili – 8 March 2022 – The gut microbiota is a well‐known prognostic factor and a modulator of treatment sensitivity in patients with cancers treated with immune checkpoint inhibitors. However, data on hepatocellular carcinoma (HCC) are lacking.
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen – 8 March 2022
Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
Anahita Rabiee, Guadalupe Garcia‐Tsao, Elliot B. Tapper – 7 March 2022
Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
Anahita Rabiee, Guadalupe Garcia‐Tsao, Elliot B. Tapper – 7 March 2022